Status:
TERMINATED
An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
MTF116086 is an open-label, randomised, parallel-design study in subjects with type II diabetes. The study is site-based, with local pharmacies serving as the sites and pharmacists as principal invest...
Eligibility Criteria
Inclusion
- Males and females of age \>=18 years
- Diagnosis of type II diabetes
- HbA1c value no higher than 9.0%
- Evidence of physician-supplied prescription for metformin use
- Stable dose of metformin for 3 months prior to enrolment
- Written informed consent from the subject
Exclusion
- Current use of any anti-diabetic medication other than metformin
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01817777
Start Date
May 1 2013
End Date
February 1 2014
Last Update
January 9 2017
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Correintes, Argentina
2
GSK Investigational Site
Corrientes, Argentina
3
GSK Investigational Site
Mendoza, Argentina, 5515
4
GSK Investigational Site
Mendoza, Argentina, 5539